A combinatorial approach to biophysically characterise chemokine-glycan binding affinities for drug development

Molecules

Volumn 19, Issue 7, 2014, Pages 10618-10634

  Gerlza, Tanja ^a   Hecher, Bianca ^a   Jeremic, Dalibor ^b   Fuchs, Thomas ^b   Gschwandtner, Martha ^a   Falsone, Angelika ^b   Gesslbauer, Bernd ^a   Kungl, Andreas J ^a,b  

^a UNIVERSITY OF GRAZ   (Austria)

^b ProtAffin Biotechnologie AG   (Austria)

Author keywords

Chemokines; Fluorescence spectroscopy; Glycosaminoglycans; Heparan sulfate; Surface plasmon resonance

Indexed keywords

ANTIINFLAMMATORY AGENT; CHEMOKINE RECEPTOR CXCR; GLYCOSAMINOGLYCAN; IL8 PROTEIN, HUMAN; INTERLEUKIN 8; PROTEIN BINDING;

ANIMAL; CELL LINE; DRUG DESIGN; GENETICS; HUMAN; INFLAMMATION; METABOLISM; PROTEIN ENGINEERING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE; DRUG DESIGN; GLYCOSAMINOGLYCANS; HUMANS; INFLAMMATION; INTERLEUKIN-8; PROTEIN BINDING; PROTEIN ENGINEERING; RECEPTORS, CXCR;

EID: 84904792994     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules190710618     Document Type: Article

References (31)

1. Falsone, A.; Wabitsch, V.; Geretti, E.; Potzinger, H.; Gerlza, T.; Robinson, J.; Adage, T.; Teixeira, M.M.; Kungl, A.J. Designing cxcl8-based decoy proteins with strong anti-inflammatory activity in vivo. Biosci. Rep. 2013, 33, 743-754.
2. Kjellen, L.; Lindahl, U. Proteoglycans: Structures and interactions. Annu. Rev. Biochem. 1991, 60, 443-475.
3. Gandhi, N.S.; Mancera, R.L. The structure of glycosaminoglycans and their interactions with proteins. Chem. Biol. Drug Des. 2008, 72, 455-482.
4. Gallagher, J.T. Heparan sulphate: A heparin in miniature. In Heparin - A Century of Progress; Springer Berlin Heidelberg: Heidelberg, Germany, 2012; Volume 207, pp. 347-360.
5. Gesslbauer, B.; Theuer, M.; Schweiger, D.; Adage, T.; Kungl, A.J. New targets for glycosaminoglycans and glycosaminoglycans as novel targets. Expert Rev. Proteomics 2013, 10, 77-95.
6. Perrimon, N.; Bernfield, M. Specificities of heparan sulphate proteoglycans in developmental processes. Nature 2000, 404, 725-728.
7. Linhardt, R.J.; Toida, T. Role of glycosaminoglycans in cellular communication. Account. Chem. Res. 2004, 37, 431-438.
8. Rollins, B.J. Chemokines. Blood 1997, 90, 909-928.
9. Coelho, A.L.; Hogaboam, C.M.; Kunkel, S.L. Chemokines provide the sustained inflammatory bridge between innate and acquired immunity. Cytokine Growth Factor Rev. 2005, 16, 553-560.
10. Johnson, Z.; Proudfoot, A.E.; Handel, T.M. Interaction of chemokines and glycosaminoglycans: A new twist in the regulation of chemokine function with opportunities for therapeutic intervention. Cytokine Growth Factor Rev. 2005, 16, 625-636.
11. Xu, D.; Esko, J.D. Demystifying heparan sulfate-protein interactions. Annu. Rev. Biochem. 2014, 83, 129-157.
12. Jin, L.; Abrahams, J.P.; Skinner, R.; Petitou, M.; Pike, R.N.; Carrell, R.W. The anticoagulant activation of antithrombin by heparin. Proc. Natl. Acad. Sci. USA 1997, 94, 14683-14688.
13. Turnbull, J.E.; Fernig, D.G.; Ke, Y.; Wilkinson, M.C.; Gallagher, J.T. Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. J. Biol. Chem. 1992, 267, 10337-10341.
14. Maccarana, M.; Casu, B.; Lindahl, U. Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J. Biol. Chem. 1993, 268, 23898-23905.
15. Blackhall, F.H.; Merry, C.L.; Davies, E.; Jayson, G.C. Heparan sulfate proteoglycans and cancer. Br. J. Cancer 2001, 85, 1094-1098.
16. Belperio, J.A.; Keane, M.P.; Arenberg, D.A.; Addison, C.L.; Ehlert, J.E.; Burdick, M.D.; Strieter, R.M. Cxc chemokines in angiogenesis. J. Leukoc. Biol. 2000, 68, 1-8.
17. Szekanecz, Z.; Kim, J.; Koch, A.E. Seminars in immunology. In Chemokines and Chemokine Receptors in Rheumatoid Arthritis; Elsevier: Amsterdam, The Netherlands, 2003; pp. 15-21.
18. Adage, T.; Piccinini, A.M.; Falsone, A.; Trinker, M.; Robinson, J.; Gesslbauer, B.; Kungl, A.J. Structure-based design of decoy chemokines as a way to explore the pharmacological potential of glycosaminoglycans. Br. J. Pharmacol. 2012, 167, 1195-1205.
19. Potzinger, H.; Geretti, E.; Brandner, B.; Wabitsch, V.; Piccinini, A.; Rek, A.; Kungl, A. Developing chemokine mutants with improved proteoglycan affinity and knocked-out GPCR activity as anti-inflammatory recombinant drugs. Biochem. Soc. Trans. 2006, 34, 435-437.
20. Piccinini, A.M.; Knebl, K.; Rek, A.; Wildner, G.; Diedrichs-Möhring, M.; Kungl, A.J. Rationally evolving mcp-1/ccl2 into a decoy protein with potent anti-inflammatory activity in vivo. J. Biol. Chem. 2010, 285, 8782-8792.
21. Brandner, B.; Rek, A.; Diedrichs-Möhring, M.; Wildner, G.; Kungl, A.J. Engineering the glycosaminoglycan-binding affinity, kinetics and oligomerization behavior of rantes: A tool for generating chemokine-based glycosaminoglycan antagonists. Protein Eng. Des. Sel. 2009, 22, 367-373.
22. Liehn, E.A.; Piccinini, A.-M.; Koenen, R.R.; Soehnlein, O.; Adage, T.; Fatu, R.; Curaj, A.; Popescu, A.; Zernecke, A.; Kungl, A.J. A new monocyte chemotactic protein-1/chemokine cc motif ligand-2 competitor limiting neointima formation and myocardial ischemia/reperfusion injury in mice. J. Am. Coll. Cardiol. 2010, 56, 1847-1857.
23. Hamel, D.J.; Sielaff, I.; Proudfoot, A.E.; Handel, T.M. Interactions of chemokines with glycosaminoglycans. Methods Enzymol. 2009, 461, 71-102.
24. Nico, J.; Fischer, M.J. Surface plasmon resonance: A general introduction. In Surface Plasmon Resonance; Springer: New York, NY, USA, 2010; pp. 1-14.
25. Freyer, M.W.; Lewis, E.A. Isothermal titration calorimetry: Experimental design, data analysis, and probing macromolecule/ligand binding and kinetic interactions. Methods Cell Biol. 2008, 84, 79-113.
26. Jelesarov, I.; Bosshard, H.R. Isothermal titration calorimetry and differential scanning calorimetry as complementary tools to investigate the energetics of biomolecular recognition. J. Mol. Recognit. 1999, 12, 3-18.
27. Lau, E.K.; Paavola, C.D.; Johnson, Z.; Gaudry, J.-P.; Geretti, E.; Borlat, F.; Kungl, A.J.; Proudfoot, A.E.; Handel, T.M. Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1 implications for structure and function in vivo. J. Biol. Chem. 2004, 279, 22294-22305.
28. Lubkowski, J.; Bujacz, G.; Boqué, L.; Alexander, W. The structure of MCP-1 in two crystal forms provides a rare example of variable quaternary interactions. Nat. Struct. Mol. Biol. 1997, 4, 64-69.
29. Osmond, R.I.W.; Kett, W.C.; Skett, S.E.; Coombe, D.R. Protein-heparin interactions measured by biacore 2000 are affected by the method of heparin immobilization. Anal. Biochem. 2002, 310, 199-207.
30. Gunay, N.S.; Linhardt, R.J. Capillary electrophoretic separation of heparin oligosaccharides under conditions amenable to mass spectrometric detection. J. Chromatogr. A 2003, 1014, 225-233.
31. Nordsieck, K.; Pichert, A.; Samsonov, S.A.; Thomas, L.; Berger, C.; Pisabarro, M.T.; Huster, D.; Beck-Sickinger, A.G. Residue 75 of interleukin-8 is crucial for its interactions with glycosaminoglycans. ChemBioChem 2012, 13, 2558-2566.